Impact of the Geographical FACTor on the Prostate Cancer Stage at Hormonal Therapy Initiation

• Status: Completed
• Trial end date: 2014-05-01
• Target enrollment: 0
• Participant gender: Male

Summary

French epidemiological data have shown a heterogeneous distribution of the risk of mortality from prostate cancer according to region. The main objective is to describe the distribution of prostate cancer stages when first line hormonal therapy is introduced (overall and by region).

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ferring Pharmaceuticals
• Treatments: Deslorelin

Criteria

Inclusion Criteria:

• Patients with histologically demonstrated prostatic adenocarcinoma.

• Patients never previously treated with hormonal therapy for prostate cancer.

• Patients eligible for hormonal therapy after initial consultation (alone or in combination with curative treatment).

• Patients agreeing to the collection of personal health data for the purposes of the study.

• Patients with locally advanced or metastatic prostatic cancer tumours or a biological recurrence after curative treatment.

Exclusion Criteria:

• Patients participating in a clinical study involving prostate cancer at the time of inclusion in the investigation.

• Patients having received or currently receiving hormonal treatment for prostate cancer (surgical castration or other hormonal manipulation, including GnRH receptor antagonists, antiandrogens, oestrogens, 5 alpha reductase inhibitors).